Enkephalins (Met-Enkephalin, Leu-Enkephalin)
Also known as: Met-Enk, Leu-Enk, Endogenous opioid peptides
Endogenous opioid peptides that modulate pain perception and mood through mu and delta opioid receptors. Researched as alternatives to traditional opioids.
Research Status
Clinical trials
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Opioid agonists can suppress respiratory drive, particularly at higher doses or with repeated administration. Monitor respiratory rate and oxygen saturation. Seek immediate medical attention if breathing becomes shallow or labored. Risk increases with concurrent CNS depressants.
Opioid-induced nausea occurs in 20-30% of users, often resolving within days as tolerance develops. Take with food or ginger supplements. Antiemetics (ondansetron) may be used if severe.
Opioids reduce GI motility. Increase fluid intake, dietary fiber, and physical activity. Stool softeners or osmotic laxatives (polyethylene glycol) are effective preventive measures.
Opioids can cause orthostatic hypotension and CNS effects. Rise slowly from sitting or lying positions. Avoid driving or operating machinery until effects are understood.
Opioid-induced itching is mediated by mast cell degranulation and histamine release. Antihistamines (cetirizine, diphenhydramine) or low-dose naloxone may provide relief.
Opioid effects on mood are variable and dose-dependent. Some users experience mild euphoria; others may experience dysphoria or emotional blunting. Monitor mood changes and report significant changes to a healthcare provider.
Repeated opioid exposure leads to receptor desensitization and reduced efficacy. Tolerance typically develops over days to weeks. Dose escalation may be necessary, but increases risk of adverse effects and dependence.
Chronic opioid use can produce physical dependence, characterized by withdrawal symptoms (anxiety, insomnia, muscle aches, sweating) upon discontinuation. Taper gradually under medical supervision to minimize withdrawal.
Opioid agonists cause pupil constriction. This is a characteristic sign of opioid activity and is generally benign but may affect vision in low-light conditions.
Redness, swelling, or mild discomfort at the injection site. Rotate injection sites to minimize risk. Apply ice if needed. Severe or persistent reactions warrant medical evaluation.
Opioids can trigger or worsen headaches in some users. Ensure adequate hydration and consider over-the-counter analgesics if needed.
Opioid-induced seizures are rare but documented, particularly at high doses or in susceptible individuals. Seek immediate medical attention if seizure activity occurs. Avoid in patients with seizure history without medical supervision.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 1-10 mcg |
| Frequency | 1-2x daily |
| Timing | Morning and/or evening, or as per research protocol |
| Route | Subcutaneous |
Dosage varies significantly depending on research application and route of administration. Start at lower end and titrate based on response. For research purposes only. Intranasal and subcutaneous routes most common in clinical research.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 573.67 Da (Met-Enkephalin); 556.64 Da (Leu-Enkephalin) |
| Half-life | 2-5 minutes (plasma); varies by tissue and route of administration |
| Sequence | Met-Enkephalin: YGGFM; Leu-Enkephalin: YGGFL |
Enkephalins are endogenous pentapeptides that bind to mu (μ) and delta (δ) opioid receptors in the central and peripheral nervous systems. They modulate pain perception by inhibiting the release of neurotransmitters involved in pain signaling and influence mood, stress response, and emotional regulation through activation of opioid receptor pathways. These peptides represent the body's natural pain-relief and mood-modulating system, making them valuable research models for understanding opioid pharmacology and developing non-addictive pain management alternatives.
Mu (μ) Opioid Receptor Signaling
Enkephalins bind to mu receptors in the spinal cord and brain, inhibiting pain signal transmission and producing analgesia. This pathway also influences mood, reward processing, and stress responses.
Delta (δ) Opioid Receptor Signaling
Delta receptor activation by enkephalins modulates pain perception, emotional responses, and may have neuroprotective effects. Delta signaling is associated with anxiolytic and mood-enhancing effects.
G-Protein Coupled Receptor (GPCR) Cascade
Opioid receptor activation triggers intracellular signaling cascades involving G-proteins, reducing cAMP levels and modulating ion channel activity, leading to decreased neuronal excitability and pain signal suppression.
Descending Pain Inhibition Pathway
Enkephalins activate inhibitory interneurons in the dorsal horn of the spinal cord, suppressing the transmission of nociceptive (pain) signals from peripheral tissues to the brain.
- Enkephalins are the first identified endogenous opioid peptides, discovered in 1975
- Met-Enkephalin and Leu-Enkephalin differ only in the C-terminal amino acid (methionine vs. leucine)
- Both peptides show preferential binding to delta receptors but also activate mu receptors
- Enkephalins are rapidly degraded by peptidases in plasma and tissues, limiting systemic bioavailability
- Research focuses on structural modifications to increase stability and receptor selectivity
- Intranasal and intrathecal routes bypass enzymatic degradation and improve CNS penetration
Track your Enkephalins (Met-Enkephalin, Leu-Enkephalin) research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Enkephalins (Met-Enkephalin, Leu-Enkephalin) is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.